Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to investigate the effects of CYP3A polymorphisms on the
pharmacokinetics of Atorvastatin in Chinese subjects with coronary heart disease.
Phase:
Phase 1
Details
Lead Sponsor:
Liuhuaqiao Hospital
Collaborator:
Guangdong Province, Department of Science and Technology